NCT01913353 - A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® | Biotech Hunter

Enrollment

440

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

August 31, 2017

Conditions

18-42 Year Old Healthy Vaccinia-naïve Subjects

Interventions

BIOLOGICAL

MVA BN®

0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection

BIOLOGICAL

ACAM2000®

0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.

Trial Locations (1)

Unknown

Brian Allgood Army Community Hospital, Seoul